Institution
Eli Lilly and Company
Company•Indianapolis, Indiana, United States•
About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Receptor. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.
Topics: Population, Receptor, Placebo, Insulin, Agonist
Papers published on a yearly basis
Papers
More filters
TL;DR: Ghrelin is considered a gastrointestinal peptide contributing to the regulation of diverse functions of the gut-brain axis and there is indeed a possibility that ghrelin analogs, acting as either agonists or antagonists, might have clinical impact.
Abstract: Ghrelin is a peptide predominantly produced by the stomach. Ghrelin displays strong GH-releasing activity. This activity is mediated by the activation of the so-called GH secretagogue receptor type 1a. This receptor had been shown to be specific for a family of synthetic, peptidyl and nonpeptidyl GH secretagogues. Apart from a potent GH-releasing action, ghrelin has other activities including stimulation of lactotroph and corticotroph function, influence on the pituitary gonadal axis, stimulation of appetite, control of energy balance, influence on sleep and behavior, control of gastric motility and acid secretion, and influence on pancreatic exocrine and endocrine function as well as on glucose metabolism. Cardiovascular actions and modulation of proliferation of neoplastic cells, as well as of the immune system, are other actions of ghrelin. Therefore, we consider ghrelin a gastrointestinal peptide contributing to the regulation of diverse functions of the gut-brain axis. So, there is indeed a possibility that ghrelin analogs, acting as either agonists or antagonists, might have clinical impact.
1,202 citations
Case Western Reserve University1, Wake Forest University2, SUNY Downstate Medical Center3, Medical University of South Carolina4, Wake Forest Baptist Medical Center5, University of Cincinnati6, University of Minnesota7, Veterans Health Administration8, University of Maryland, Baltimore9, Eli Lilly and Company10, Oregon Health & Science University11, New York University12, HealthPartners13, University of Michigan14, Albert Einstein College of Medicine15, University of Arkansas for Medical Sciences16, Henry Ford Hospital17
TL;DR: Intensive therapy did not reduce the risk of advanced measures of microvascular outcomes, but delayed the onset of albuminuria and some measures of eye complications and neuropathy.
1,174 citations
TL;DR: It is found that TREM2 deficiency and haploinsufficiency augment β-amyloid accumulation due to dysfunctional response of microglia, which become apoptotic and fail to cluster around Aβ plaques.
1,146 citations
TL;DR: An assessment of the current state of the art in green chemistry and green engineering areas and to highlight areas for future improvement are provided.
1,140 citations
TL;DR: Chronic pain, experienced by about a third of the population, was correlated with indicators of poorer socioeconomic status and low household income and unemployment as significant socioeconomic correlates of chronic pain.
1,119 citations
Authors
Showing all 17866 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Mark J. Daly | 204 | 763 | 304452 |
| Irving L. Weissman | 201 | 1141 | 172504 |
| Eric J. Topol | 193 | 1373 | 151025 |
| Tony Hunter | 175 | 593 | 124726 |
| Xiang Zhang | 154 | 1733 | 117576 |
| Jerrold M. Olefsky | 143 | 595 | 77356 |
| Stephen F. Badylak | 133 | 530 | 57083 |
| George A. Bray | 131 | 896 | 100975 |
| Lloyd Paul Aiello | 131 | 506 | 85550 |
| Levi A. Garraway | 129 | 366 | 99989 |
| Mark Sullivan | 126 | 802 | 63916 |
| James A. Russell | 124 | 1024 | 87929 |
| Tony L. Yaksh | 123 | 806 | 60898 |
| Elisabetta Dejana | 122 | 430 | 48254 |
| Hagop S. Akiskal | 118 | 565 | 50869 |